Autoimmune Diseases Working Party (ADWP)
Type d'étude:
Numéro de l'étude:
8410026
Type de traitement à base de cellules souches:
Autologous
Maladies:
Auto immune disorders
Titre court:
BEAMCYC
Objectif principal:
Provide data about safety and efficacy of HD-Cyclophosphamide/ATG vs BEAM/ATG conditioning regimens in severe Multiple Sclerosis
Principaux critères d'inclusion:
• Diagnosis of MS according to the 2010 revised McDonald’s criteria
• Availability of a detailed MS clinical history, including disability progression and relapse rate in the 2 years before the HSCT
• Availability of information about previous DMAs administered
• Patients aged 18 or more at time of transplant
• First aHSCT
• Availability of a clinical follow-up, including regular neurological assessment and MRI scans.
• Availability of a detailed MS clinical history, including disability progression and relapse rate in the 2 years before the HSCT
• Availability of information about previous DMAs administered
• Patients aged 18 or more at time of transplant
• First aHSCT
• Availability of a clinical follow-up, including regular neurological assessment and MRI scans.
Pays:
Investigateur principal:
Riccardo Saccardi
Coordinateur EBMT de l'étude:
Manuela Badoglio
E-mail du coordinateur de l'étude:
manuela.badoglio@upmc.fr